Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study.
Medications for opioid use disorder
Opioid use disorder
Residential treatment
Treatment
Journal
Addiction science & clinical practice
ISSN: 1940-0640
Titre abrégé: Addict Sci Clin Pract
Pays: England
ID NLM: 101316917
Informations de publication
Date de publication:
19 08 2022
19 08 2022
Historique:
received:
07
07
2021
accepted:
01
07
2022
entrez:
19
8
2022
pubmed:
20
8
2022
medline:
24
8
2022
Statut:
epublish
Résumé
Residential treatment is a common approach for treating opioid use disorder (OUD), however, few studies have directly compared it to outpatient treatment. The objective of this study was to compare OUD outcomes among individuals receiving residential and outpatient treatment. A retrospective cohort study used linked data from a state Medicaid program, vital statistics, and the Substance Abuse and Mental Health Services Administration (SAMHSA) Treatment Episodes Dataset (TEDS) to compare OUD-related health outcomes among individuals treated in a residential or outpatient setting between 2014 and 2017. Multivariable Cox proportional hazards and logistic regression models examined the association between treatment setting and outcomes (i.e., opioid overdose, non-overdose opioid-related and all-cause emergency department (ED) visits, hospital admissions, and treatment retention) controlling for patient characteristics, co-morbidities, and use of medications for opioid use disorders (MOUD). Interaction models evaluated how MOUD use modified associations between treatment setting and outcomes. Of 3293 individuals treated for OUD, 957 (29%) received treatment in a residential facility. MOUD use was higher among those treated as an outpatient (43%) compared to residential (19%). The risk of opioid overdose (aHR 1.39; 95% CI 0.73-2.64) or an opioid-related emergency department encounter or admission (aHR 1.02; 95% CI 0.80-1.29) did not differ between treatment settings. Independent of setting, MOUD use was associated with a significant reduction in overdose risk (aHR 0.45; 95% CI 0.23-0.89). Residential care was associated with greater odds of retention at 6-months (aOR 1.71; 95% CI 1.32-2.21) but not 1-year. Residential treatment was only associated with improved retention for individuals not receiving MOUD (6-month aOR 2.05; 95% CI 1.56-2.71) with no benefit observed in those who received MOUD (aOR 0.75; 95% CI 0.46-1.29; interaction p = 0.001). Relative to outpatient treatment, residential treatment was not associated with reductions in opioid overdose or opioid-related ED encounters/hospitalizations. Regardless of setting, MOUD use was associated with a significant reduction in opioid overdose risk.
Sections du résumé
BACKGROUND
Residential treatment is a common approach for treating opioid use disorder (OUD), however, few studies have directly compared it to outpatient treatment. The objective of this study was to compare OUD outcomes among individuals receiving residential and outpatient treatment.
METHODS
A retrospective cohort study used linked data from a state Medicaid program, vital statistics, and the Substance Abuse and Mental Health Services Administration (SAMHSA) Treatment Episodes Dataset (TEDS) to compare OUD-related health outcomes among individuals treated in a residential or outpatient setting between 2014 and 2017. Multivariable Cox proportional hazards and logistic regression models examined the association between treatment setting and outcomes (i.e., opioid overdose, non-overdose opioid-related and all-cause emergency department (ED) visits, hospital admissions, and treatment retention) controlling for patient characteristics, co-morbidities, and use of medications for opioid use disorders (MOUD). Interaction models evaluated how MOUD use modified associations between treatment setting and outcomes.
RESULTS
Of 3293 individuals treated for OUD, 957 (29%) received treatment in a residential facility. MOUD use was higher among those treated as an outpatient (43%) compared to residential (19%). The risk of opioid overdose (aHR 1.39; 95% CI 0.73-2.64) or an opioid-related emergency department encounter or admission (aHR 1.02; 95% CI 0.80-1.29) did not differ between treatment settings. Independent of setting, MOUD use was associated with a significant reduction in overdose risk (aHR 0.45; 95% CI 0.23-0.89). Residential care was associated with greater odds of retention at 6-months (aOR 1.71; 95% CI 1.32-2.21) but not 1-year. Residential treatment was only associated with improved retention for individuals not receiving MOUD (6-month aOR 2.05; 95% CI 1.56-2.71) with no benefit observed in those who received MOUD (aOR 0.75; 95% CI 0.46-1.29; interaction p = 0.001).
CONCLUSIONS
Relative to outpatient treatment, residential treatment was not associated with reductions in opioid overdose or opioid-related ED encounters/hospitalizations. Regardless of setting, MOUD use was associated with a significant reduction in opioid overdose risk.
Identifiants
pubmed: 35986384
doi: 10.1186/s13722-022-00318-1
pii: 10.1186/s13722-022-00318-1
pmc: PMC9389731
doi:
Substances chimiques
Analgesics, Opioid
0
Buprenorphine
40D3SCR4GZ
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
45Subventions
Organisme : NIDA NIH HHS
ID : K23 DA053390
Pays : United States
Organisme : NIDA NIH HHS
ID : UG1 DA015815
Pays : United States
Organisme : NIDA NIH HHS
ID : UG3 DA044831
Pays : United States
Organisme : NIDA NIH HHS
ID : UH3 DA044831
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Am J Addict. 2003 Oct-Dec;12(5):386-97
pubmed: 14660153
JAMA Netw Open. 2020 Feb 5;3(2):e1920622
pubmed: 32022884
Lancet. 2019 Apr 27;393(10182):1760-1772
pubmed: 30878228
JAMA Netw Open. 2020 Dec 1;3(12):e2029676
pubmed: 33320266
J Gen Intern Med. 2020 Nov;35(11):3188-3196
pubmed: 32935311
J Subst Abuse Treat. 2015 Jun;53:16-21
pubmed: 25736624
JAMA Netw Open. 2020 Feb 5;3(2):e1920843
pubmed: 32031650
BMJ. 2017 Apr 26;357:j1550
pubmed: 28446428
J Subst Abuse Treat. 2006 Dec;31(4):439-45
pubmed: 17084799
Addiction. 2005 Aug;100(8):1090-100
pubmed: 16042639
Addict Behav. 2016 Jul;58:129-35
pubmed: 26925821
Med Care. 2009 Jun;47(6):626-33
pubmed: 19433995
JAMA. 2020 Aug 25;324(8):804-806
pubmed: 32840587
Drug Alcohol Depend. 2016 Dec 01;169:117-127
pubmed: 27810654
MMWR Morb Mortal Wkly Rep. 2015 Apr 17;64(14):377-80
pubmed: 25879895
JAMA Psychiatry. 2021 Sep 1;78(9):979-993
pubmed: 34076676
J Addict Med. 2021 Apr 1;15(2):130-133
pubmed: 32732683
Psychiatr Serv. 2014 Mar 1;65(3):301-12
pubmed: 24445598
J Subst Abuse Treat. 2015 Oct;57:75-80
pubmed: 25997674
Med Care. 2001 Nov;39(11):1158-69
pubmed: 11606870
Ann Intern Med. 2019 Mar 19;170(6):430-431
pubmed: 30884508
Addiction. 2020 Jan;115(1):82-94
pubmed: 31430414
Annu Rev Public Health. 2018 Apr 1;39:525-541
pubmed: 29272165
J Addict Dis. 2003;22 Suppl 1:45-60
pubmed: 15991589
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Pain. 2022 Jan 1;163(1):83-90
pubmed: 33863865
JAMA Pediatr. 2018 Nov 1;172(11):1029-1037
pubmed: 30208470
Cochrane Database Syst Rev. 2011 Sep 07;(9):CD005031
pubmed: 21901695
Pharmacoepidemiol Drug Saf. 2019 Aug;28(8):1127-1137
pubmed: 31020755
Brain Dev. 2002 Mar;24(2):130-9
pubmed: 11891107
J Subst Abuse Treat. 2022 Jan;132:108615
pubmed: 34600772
Health Aff (Millwood). 2019 Jan;38(1):14-23
pubmed: 30615514
Drug Alcohol Depend. 2014 Apr 1;137:76-82
pubmed: 24529966
Med Care. 1998 Jan;36(1):8-27
pubmed: 9431328
J Addict Dis. 2003;22 Suppl 1:79-93
pubmed: 15991591
Med Care. 2017 Jul;55(7):698-705
pubmed: 28498196
Addiction. 2020 Aug;115(8):1496-1508
pubmed: 32096908